NCT00391690View on ClinicalTrials.gov

Evaluation of Bone Markers as Diagnostic Tools for Early Detection of Bone Metastases in Patients With High Risk Prostate Cancer

PHASE4CompletedINTERVENTIONAL
Enrollment

99

Participants

Timeline

Start Date

February 28, 2006

Primary Completion Date

December 31, 2010

Conditions
Prostate Cancer
Interventions
DRUG

Zoledronic acid

In case of bone metastases: Zoledronic acid every 4 weeks for 3 months.

Trial Locations (1)

Unknown

Novartis Investigative Site, Tübingen

Sponsors

Lead Sponsor

Novartis
All Listed Sponsors
lead

Novartis

INDUSTRY